New Key Statistics Module, Z-Score and F-Score
NAS:ERNA Key Ratios
| Market Cap $ M | 15.10 |
| Enterprise Value $ M | 43.62 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | -- |
| Price/Sales | 2.57 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | -- |
| EPS (TTM) $ | -8.31 |
| Beneish M-Score | -1.72 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -- |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -1.06 |
| EV-to-EBITDA | -1.12 |
| PEG | -- |
| Shares Outstanding M | 51.37 |
| Net Margin (%) | -7,513.88 |
| Operating Margin % | -3,397.49 |
| Pre-tax Margin (%) | -7,511.37 |
| Quick Ratio | 0.48 |
| Current Ratio | 0.48 |
| ROA % (ttm) | -109.46 |
| ROE % (ttm) | -- |
| ROIC % (ttm) | -52.80 |
| Dividend Yield % | -- |
| Altman Z-Score | -59.11 |
ERNA Number of Guru Trades
ERNA Volume of Guru Trades
Gurus Latest Trades with NAS:ERNA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:ERNA is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Eterna Therapeutics Inc Insider Transactions
No Available Data
News about NAS:ERNA
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers